Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - HeartWare International, Inc. | c15651exv99w2.htm |
| EX-99.1 - EXHIBIT 99.1 - HeartWare International, Inc. | c15651exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 15, 2011
HEARTWARE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34256 | 26-3636023 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 205 Newbury Street, Suite 101 Framingham, MA |
01701 |
|
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 508.739.0950
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events
At 4:00 p.m (Pacific time) on April 15, 2011, Mark S. Slaughter, M.D., Professor and Chief in the
Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and
Heart Transplant Program at the University of Louisville, and Principal Investigator for HeartWare
International, Inc.’s bridge-to-transplant study ADVANCE, presented an update to clinical data from
ADVANCE, as well as from the Continued Access Protocol for that study at The International Society
of Heart and Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions in
San Diego.
HeartWare International, Inc. (ASX:HIN: NASDAQ:HTWR), a leading innovator of less invasive,
miniaturized circulatory support technologies that are revolutionizing the treatment of advanced
heart failure, held a webcast investor breakout session following the scientific presentation.
Management was joined by Dr. Slaughter and Professor Thomas Krabatsch, M.D., Ph.D., Department of
Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin.
A copy of the slides presented by Dr. Slaughter at ISHLT is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
A copy of a press release issued by HeartWare ISHLT is attached hereto as Exhibit 99.2 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 Slides presented by Dr. Mark S. Slaughter at The International Society of Heart and
Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions in San Diego on
April 15, 2011.
Exhibit 99.2 HeartWare International, Inc. press release dated April 15, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HeartWare International, Inc. |
||||
| Date: April 15, 2011 | By: | /s/ Douglas Godshall | ||
| Name: | Douglas Godshall | |||
| Title: | Chief Executive Officer | |||